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STATE-OF-THE-ART REVIEWFunctional Tricuspid Regurgitation
A Need to Revise Our UnderstandingGilles D. Dreyfus, MD, PHD,*y Randolph P. Martin, MD,z K.M. John Chan, PHD,*yx Filip Dulguerov, MD,*
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MaThe assessment of the etiology and severity of functional tricuspid regurgitation (FTR) has many limitations, especially
when tricuspid regurgitation (TR) is more than severe. Instead of relying solely on TR severity, a new approach not only
takes into account the severity of TR, but also pays strict attention to tricuspid annular dilation (size), the mode of
tricuspid leaﬂet coaptation, and tricuspid leaﬂet tethering—factors often inﬂuenced by right ventricular enlargement
and dysfunction. To simplify things, we propose a new staging system for functional tricuspid valve pathology using
3 parameters that may more accurately reﬂect the severity of the disease: TR severity, annular dilation, and mode of
leaﬂet coaptation (extent of tethering). We believe that by utilizing these parameters, cardiologists and cardiac surgeons
will be offered a better system for appraisal and decision-making in FTR. (J Am Coll Cardiol 2015;65:2331–6)
© 2015 by the American College of Cardiology Foundation.F unctional tricuspid regurgitation (FTR) isprimarily due to tricuspid annulus (TA) dilationand right ventricular enlargement and dysfunc-
tion, which lead to abnormalities of tricuspid anatomy
and function. FTR ismost often secondary to left-sided
heart disease, especially in the setting of mitral valve
pathology (1). Themost frequent left-sided heart valve
diseases, which can, in turn, lead to FTR, are mitral
regurgitation (MR), mitral stenosis, and aortic steno-
sis. It is also important to note that atrial ﬁbrillation,
especially if chronic, can be an important etiologic fac-
tor in the development of FTR, primarily through its
effect on tricuspid annular dilation (1,2). With the
increasing recognition of mitral valve diseases, it is
also noteworthy that approximately 30% to 50% of
patients with severe MR have signiﬁcant FTR (3,4).
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dysfunction, which can lead to abnormalities of
the tricuspid annular size, as well as tricuspid leaﬂet
tethering problems, all of which can also produce sig-
niﬁcant FTR (Central Illustration). Patients with signif-
icant FTRmay remain asymptomatic, despite impaired
right ventricular function. FTR carries an adverse
prognosis, which is related to its severity (5). The
severity of tricuspid regurgitation (TR) is often the
only parameter measured when assessing FTR; how-
ever, it is not the only criterion that should be utilized
when evaluating the pathological processes and
severity involved in FTR.
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2332tricuspid leaﬂet coaptation and produce
tricuspid valve (TV) tethering. Because the
right ventricle (RV) is more compliant than the
left ventricle, the RV size may easily double
without affecting its function. Currently,
assessment by noninvasive imaging of right
ventricular global size and function is less
reliable than assessment of left ventricular size
and function. However, when assessing FTR,
it is very important to have a systematic
approach to judging its effect—based not only
on the severity of the TR, but also upon
tricuspid annular size,mode of tricuspid leaﬂet
coaptation, as well as the extent of tricuspid
leaﬂet tethering. All of these taken together
will help guide decision-makingwith respect to
the need for concomitant surgical intervention
on the TV during left-sided heart valve surgery,particularly when TR is less severe. These parameters
will also help in determining whether additional surgi-
cal repair techniques are needed during TV surgery.
TV AND ANNULAR ANATOMY
The TV is made of 3 leaﬂets, but not all leaﬂets play
an equal role in FTR. The septal leaﬂet, whoseFunctional Tricuspid Regurgitation Development, A
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FTR ASSESSMENTS
l. 2015; 65(21):2331–6.papillary muscle is attached to the septum, is affected
by the septal shift from right to left, but this is usually
limited. The posterior leaﬂet is the smallest of the 3,
and its papillary muscle is attached to the inferior
wall of the RV. Thus, the diaphragm limits its dis-
placement. The anterior leaﬂet is the biggest in sur-
face area and is almost always anchored to a single
papillary muscle, which is attached to the free wall or
the anterior wall of the RV. This most important of
TV leaﬂets is greatly affected by annular dilation, and
TR appears when it is sufﬁcient enough to reduce
the coaptation height to a minimum. As the annulus
dilates, the anterior and posterior leaﬂets are pulled
away from the coaptation point, resulting in gaps
that create TR jets (6). Papillary muscle displace-
ment, another mechanism to explain FTR, is cor-
related with RV dilation. In such conditions, the
papillary muscles become displaced, resulting in a
changing of the position of the coaptation point and
in leaﬂet tethering (6).
The TA is a very complex and dynamic structure,
which changes its shape and size during the cardiac
cycle. The TA, although saddle- or oval-shaped, is
nonplanar. Although it is currently evaluated by
2-dimensional echocardiography (2DE) (both trans-
thoracic and transesophageal), it is likely betterssessment, Diagnosis, and Treatment
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2333assessed with 3-dimensional echocardiography (3DE).
Because of the changes in the TA shape and size
during the cardiac cycle, as well as changes secondary
to alterations in RV size and function, the best
method for determining TA size and assessing the
degree of regurgitation is yet to be established.
Because of the changes in the TA shape and size
during the cardiac cycle, as well as changes secondary
to alterations in RV size and function, there is yet to
be an established best method for determining TA
size and assessing degree of regurgitation, both of
which are dynamic processes that could alter not only
with the phases of cardiac cycle, but with respiratory
changes as well.
SEVERITY OF TR
Judging the severity of TR by echocardiography has
often proved difﬁcult, whether by qualitative, semi-
quantitative, or quantitative techniques. This is
especially prominent in less severe TR (7,8). Echo-
cardiographic methods of assessing TR severity are
based primarily on techniques used for assessing MR
severity. However, there are important differences
between the 2 valves and their oriﬁces, subvalvular
apparatuses, and respective ventricles. Although the
major method used to evaluate severity of TR is pre-
dominantly color ﬂow jet visualization, it is important
to realize that the color Doppler TR jet is often vari-
able, depending upon the echocardiographic window
used. Also of critical importance is the fact that the
color jet is a mean velocity map, not a ﬂow map, and
is affected by many factors, including instrument
setting and hemodynamics, among others. It is
equally important to understand that the type of
regurgitant oriﬁce affects the shape and distribution
of the color jet in the right atrium. Semiquantitative
methods also have signiﬁcant limitations in trying to
quantitate the severity of TR. The recent American
Heart Association (AHA)/American College of Cardi-
ology (ACC) guidelines (9) primarily use the vena
contracta in an attempt to quantitate the severity of
TR. The vena contracta is the smallest high-velocity
region of the ﬂow jet on the atrial side of the
tricuspid oriﬁce. Vena contracta measurements at-
tempt to measure the width of this high-velocity
region of ﬂow. If the regurgitant oriﬁce is truly cir-
cular, it correlates with the effective regurgitant
oriﬁce area in primary MR. However, if the regurgitant
oriﬁce is elliptical, its measurement and accuracy are
more problematic. Hence, vena contracta measure-
ments are not accurate with elliptical slit-like oriﬁces
when multiple jets are present. Also, as previously
mentioned, the measured width of the vena contractais markedly dependent upon which portion of systole
it is measured in. A vena contacta width >6.5 mm (7.0
mm in the recent ACC/AHA guidelines) is used to
indicate severe TR. However, current guidelines do
not substantiate which vena contracta width should
be used to differentiate mild TR from moderate TR.
Although the vena contracta width has been
included in the latest ACC/AHA and European Society
of Cardiology/European Association of Cardio-
Thoracic Surgery guidelines as a method for judging
the severity of TR, the tricuspid regurgitant oriﬁce is
seldom circular and may, in fact, be more star-shaped
(due to failure of proper coaptation along the 3 com-
missures of the TV) or even slit-like, producing mul-
tiple jets of TR. This limits the usefulness of the vena
contracta as a quantitative marker of TR severity and
FTR. Although evaluation of proximal isovelocity
surface area (PISA) radius is not included in the cur-
rent ACC guidelines, the published data suggest that
a PISA radius >9 mm at a Nyquist limit of 28 m/s
is indicative of severe TR. A PISA radius <5 mm is
indicative of mild TR. But, as is well-recognized with
PISA measurements for MR, eccentric regurgitant
jets prevent beam alignment and limit this tech-
nique’s accuracy with standard 2-dimensional imag-
ing. The published data also suggest that an effective
regurgitant oriﬁce >40 mm2 or a regurgitant volume
>45 ml is indicative of severe TR. However, the
reproducibility of these measurements and, again,
the variability of the TR with alterations in respiration
and right ventricular function make this measure-
ment of limited utility. Also, there are no quantitative
criteria for grading mild and moderate TR, and it is
not possible to distinguish between the 2 grades of TR
using quantitative grading. It must be emphasized
that respiratory changes in TR are extremely impor-
tant to recognize, as are the inﬂuences of pre-load,
afterload, and alterations in right ventricular func-
tion. It is well recognized that the tricuspid regur-
gitant oriﬁce area increases with inspiration, due to
both enlargement of the TA as well as alterations in
valve tenting. However, qualitative and quantitative
measurements of TR severity have seldom taken this
into account.
PROPOSED NEW METHOD FOR ASSESSING
THE TRICUSPID APPARATUS IN FTR
The assessment of FTR should be revised to better aid
clinical decision and management. As mentioned
previously, we believe that this should be on the
basis of 3 criteria that can be measured by echocar-
diography: TR severity, the tricuspid annular diam-
eter, and the mode of tricuspid leaﬂet coaptation
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2334(leaﬂet tethering). We agree wholeheartedly with
the recent simpliﬁcation of tricuspid grading into
3 grades (8). However, we suggest that TR should
be divided not by grades, but as follows: no TR and
mild TR should be 1 entity; mild-moderate and mod-
erate TR should be a second entity; and severe
TR should be a third entity. We recognize that
TR grading is extremely labile, echocardiographic
window-dependent, respiratory-dependent, and that
sequential analyses should be performed.
TRICUSPID ANNULAR ASSESSMENT
Currently, the TA is measured and identiﬁed by
various echocardiographic views for identifying
annular insertion of the tricuspid leaﬂets. As the
tricuspid leaﬂets occupy 3-dimensional (3D) space,
they are, therefore, better evaluated by 3DE. Multiple
authors have shown that 3DE brings better spatial
evaluation of TV anatomy because it mimics an
intraoperative surgical view and offers better identi-
ﬁcation of valvular leaﬂets and their variability (8,10).
3DE has many advantages when evaluating organic
or structural TV lesions, such as rheumatic leaﬂet
restriction or interference between pacemaker wire
and septal leaﬂets (11). In the setting of FTR, trans-
thoracic 3DE has been demonstrated to be more
accurate in measurements of tricuspid annular size
than 2DE (8). Data is currently limited as to the value
of transesophageal echocardiography (TEE), espe-
cially 3D-TEE, but it is the impression of many that
3DE, whether 2DE or TEE, will become the standard
procedure for accurately measuring tricuspid annular
dimensions (Central Illustration).
Tricuspid leaﬂet anatomy is currently assessed by
routine transthoracic 2DE. It must be recognized
that, from the apical 4-chamber view, as well as from
the parasternal short-axis view, angulation of the
transducer will determine which 2 of the 3 tricuspid
leaﬂets are best visualized. Many experienced echo-
cardiographers believe that the best way to identify
the leaﬂets themselves, as well as annular dimen-
sions, is with subcostal short-axis views of all 3
tricuspid leaﬂets, as well as transgastric TEE views
of all 3 tricuspid leaﬂets.
Currently, tricuspid annular diameters are mea-
sured in diastole from the apical 4-chamber view. This
gives a measurement from approximately the mid-
septal annulus to the midanterior annulus (although it
could be the posterior) and has been shown to be a
predictor of the severity of TR (12). The TA is consid-
ered dilated when it is >40 mm (9). In 2005, Dreyfus
et al. (13) published a series of 311 patients for whom
tricuspid annular dilation was the triggering factorfor surgical correction, irrespective of the grading of
TR severity. In most of these patients, despite the
absence of signiﬁcant TR, the TA was signiﬁcantly
dilated. Performance of tricuspid annuloplasty resul-
ted in improved New York Heart Association func-
tional class and prevented progression of FTR in
long-term follow-up. Others have more recently re-
ported similar results (14,15). Dreyfus et al. (13) used a
threshold of annular diameter of 70 mm measured
intraoperatively from the anterior septal commissure
to the anterior posterior commissure. This corre-
sponded to a diameter of 40 mm, as measured by
echocardiography from an apical 4-chamber view.
We are well aware that using a measurement of
40mm, obtained from the 4-chamber view,may not be
accurate. Tricuspid annular diametermeasured by 2DE
is known to systematically underestimate the actual
TA diameter when comparedwith 3D-TEE. However, it
is 1 of the initial steps that can be used to evaluate
annular size. Again, depending upon how the echo-
cardiographic beam is aimed, it will intersect the
septal–anterior annulus or septal–posterior annulus.
Recognizing its limitations, we believe that the mea-
surement has 2 main advantages. First, transthoracic
2DE is a routine technique, as opposed to 3DE or even
3D-TEE. Second, viewing the TA from the 4-chamber
2DE view has been stated to estimate the size of the
TA. Hence, this threshold value of 40mm (or 21mm/m2
diameter indexed to body surface area) is the size
mentioned in the most recent ACC/AHA guidelines,
and in the European Society of Cardiology Guidelines
it is a Level IIa indication for a tricuspid surgical
annuloplasty when associated with mild or moderate
TR (9). However, we again emphasize that other views,
particularly subcostal short-axis views of the TV and
transesophageal views of the TV—especially trans-
gastric—may be more accurate, especially when
coupledwith 3D imaging to accuratelymeasure the TA.
MODE OF LEAFLET COAPTATION
The third criterion that we propose—leaﬂet coaptation—
should be analyzed carefully. The coaptation is the
surface of contact between the leaﬂets that is
measured indirectly by coaptation height. The greater
the coaptation, the less regurgitation is likely to occur.
A safe coaptation takes place between the body of
each leaﬂet and, therefore, is called body-to-body
coaptation. If, for any reason (annular dilation,
leaﬂet tethering), the coaptation surface is decreased,
then coaptation can take place on the free edge of the
leaﬂet, either symmetrically (edge-to-edge) or asym-
metrically (edge-to-body). In these cases, the likeli-
hood of developing TR becomes very high, as,
TABLE 1 Stages of Functional Tricuspid Regurgitation
Stage 1 Stage 2 Stage 3
TR severity None or mild Mild or moderate Severe
Annular diameter, mm <40 >40 >40
Leaﬂet coaptation
mode
Normal* Edge-to-edge* Absent†
Treatment Medical treatment Tricuspid annuloplasty Tricuspid annuloplasty
þ leaﬂet augmentation‡
*No leaﬂet tethering (<8 mm). †Leaﬂet tethering may be present ($8 mm). ‡If leaﬂet tethering is present.
TR ¼ tricuspid regurgitation.
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2335according to ﬁlling conditions, there is no longer any
safety margin to compensate or avoid regurgitation.
The next step is a lack of coaptation, where the leaﬂets
never meet. Coaptation is affected by many more
variables on the right side, as opposed to the left side.
Hence, due to more rapid changes in RV size, shape,
and function, the mode of leaﬂet coaptation is more
relevant on the right side. Normal coaptation of the
tricuspid leaﬂets during systole takes place either at
the level of the annulus or apically, just below it, with
a good surface-to-surface coaptation (about 5 to 10 mm
of the leaﬂets’ bodies in contact with each other dur-
ing systole). From the apical 4-chamber view, the
septal and anterior leaﬂets are usually seen, although
it can also be the septal and posterior leaﬂets. As soon
as annular dilation occurs, the leaﬂet coaptation mode
tends to become edge-to-edge. If the RV dilates at the
same time, which is part of the same pathophysiologic
process, then not only is coaptation edge-to-edge, but
it also occurs below the annular plane. It must be
emphasized that the mode of leaﬂet coaptation is an
important consideration when deciding on the need
for surgical intervention. For example, an edge-to-
edge leaﬂet coaptation with mild TR and an annular
diameter of >40 mm is indicative of signiﬁcant
tricuspid valvular pathology and should be considered
for tricuspid annuloplasty, as any changes in pre-load,
afterload, and right ventricular function will elicit
more regurgitation. If leaﬂet coaptation is occurring
below the annular plane, then it can also be called
surface-to-surface or edge-to-edge. The distance of
leaﬂet coaptation point from the plane of the TA can
be measured and is called the tethering distance. The
area contained within the leaﬂets and the annular
plane can be measured and is called the tenting area.
Leaﬂet tethering is considered signiﬁcant when the
tethering difference is >8 mm or the tenting area is
>1.6 cm2 (12). When signiﬁcant leaﬂet tethering is
present, no leaﬂet coaptation occurs at any stage of the
cardiac cycle, thereby creating a single cavity between
the RV and the right atrium. With 3DE, the extent of TV
tethering can be measured in terms of tenting volume,
and this parameter may be more accurate (16). The
concept of TV tenting is not as well appreciated as an
entity that requires speciﬁc surgical treatment, such as
those that we have previously described (14). TV tent-
ing volume has also been reported to independently
determine residual TR after tricuspid annuloplasty. In
predicting residual TR after tricuspid annuloplasty, a
TV tenting volume >2.3 ml shows a sensitivity of 100%
and a speciﬁcity of 84% (16). It must be emphasized
that signiﬁcant tethering does not necessarily indicate
tricuspid valve replacement, as we have shown with
anterior leaﬂet extension techniques (17).SUMMARY
Using these parameters, we suggest classifying func-
tional TV pathology into 3 stages that can help in
decision making on the basis of TR grading, annular
dilation, and leaﬂet coaptation mode (Table 1). Stage
1: there is no or mild TR; the TA is not dilated,
measuring <40 mm; and leaﬂet coaptation is normal,
occurring at the level of the annulus and with a good
surface of coaptation between the leaﬂets. Stage 2:
there is mild or moderate TR, the TA is dilated to
>40 mm, and leaﬂet coaptation is impaired, occurring
only at the edges. Stage 3: there is severe TR; the
annulus is dilated to >40 mm; leaﬂet coaptation is
impaired, occurring only at the edges or not at
all; and there may additionally be leaﬂet tethering
with the coaptation or theoretical coaptation point
occurring $8 mm below the level of the annulus. This
new staging system for functional tricuspid valvular
pathology, which combines more than 1 parameter,
offers a more consistent and reliable guide with
respect to the need for surgical intervention on the
TV during left-sided heart valve surgery and also
the type of surgery required (Central Illustration).
In Stage 1 disease, no surgical intervention is
indicated. In Stage 2 disease, concomitant TV valve
annuloplasty is recommended. For decades, it was
believed that FTR would spontaneously disappear
after correction of the MR. However, we now know
that this is not true in most cases and that FTR is, in
fact, a progressive disease if left uncorrected at
the time of left-sided heart valve surgery (13,15). We
have previously demonstrated that tricuspid annular
dilation can be present without signiﬁcant TR and
that performing an annuloplasty results in improved
New York Heart Association functional class and
prevents progression of the TR, which occurs when
tricuspid annuloplasty is not performed (13). Others
have more recently reported similar results. In an
observational study, Navia et al. (14) reported that
the risk of developing subsequent severe secondary
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the time of initial surgery. Similarly, in a randomized
trial of patients with moderate TR and tricuspid
annular dilation (>40 mm), Benedetto et al. (15) re-
ported that TR was absent at 1 year in 71% of those
who received an annuloplasty compared with 19%
in those who did not. Severe TR was present in 0%
of the annuloplasty group versus 28% of the non-
annuloplasty group. Yilmaz et al. (18) reported in an
observational study that 13% of patients had moder-
ate or worse TR at the time of mitral valve surgery,
which was not treated. At 5 years, this had increased
to 29.9%, a progression of untreated TR similar to
that observed in our previous reports (13,18). In this
study, only 1 patient required reoperation for severe
TR at 4.5 years. However, there are no established
criteria for reoperation due to severe TR, as many
factors must be considered, including pulmonary
hypertension, right ventricular function and stroke
volume, and liver and renal function. The reoperation
rate for severe TR cannot be considered a valid
endpoint in studies on TV surgery, as it is too sub-
jective and depends on the clinician. Other factors
that can contribute to progression of FTR should also
be considered, such as untreated or new-onset atrialﬁbrillation, post-capillary pulmonary hypertension
related to residual or recurrent MR, or persistent left
ventricular dysfunction.
In Stage 3 disease, concomitant tricuspid annulo-
plasty is also recommended. In addition, if signiﬁ-
cant leaﬂet tethering is present, augmenting the
anterior tricuspid leaﬂet is recommended to ensure
good long-term results and avoid recurrent TR. This
is a surgical technique that we have previously
described (17,19) and have been using for >10 years,
with excellent long-term results showing reverse
remodeling of the RV.
Recognizing how labile TR severity can be, FTR
should be revisited from its initial assessment,
including other parameters of tricuspid valvular pa-
thology. TR must be recognized as a severe disease,
which reduces survival, limits functional capacity,
and causes end organ dysfunction. There is no
effective medical therapy for TR, and appropriate
referral for surgical intervention is necessary.
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